肺癌摘要和讨论王洁.pptVIP

Goss, et al. J.C..O, 2009:27 * Goss, et al. J.C..O, 2009:27 * Goss, et al. J.C..O, 2009:27 Inoun A, et al J.Clin.Oncol, 2009,27 Conclusion:Ps 2 or poorer patients with advanced NSCLC A carboplatin doublet is generally well tolerated by PS2 patients nd leads to a higher response and lower progression rate compared to single agent therapy. Impact on overall survival is less discernible. Despite toxicity concerns, there is no apparent detriment in QOL in QOL. EGFR-TKI is an acceptable alternative for PS2 or poorer patients, but its best use should be those selected by EGFR mutation. Better identification of PS2 patients who benefit from carboplatin doublet is an important research goal. * * * * * * * * * * * * Dear chairmen, dear friends, dear colleagues, I feel very honoured to present here on behalf of the French Intergroup of Thoracic Oncology the results of a phase III study comparing weekly paclitaxel combined with monthly carboplatin versus single agent therapy in patients aged 70 to 89 with advanced non-small cell lung cancer. This study has been supported by the french national cancer Institute and the league against cancer. * The rapid increase in the number of lung cancers in the elderly is a result of both increased life expectancy and increased incidence of cancers with age. The median age of lung cancer patients is between 65 and 69 years. More than one-third of the patients are aged over 70. * The first rqtionqle of the study is a very important trial was published in 1999 by the Italian lung cancer study group comparing vinorelbine to best supportive care in 154 patients aged 70 and over. There was a significant benefit of treatment with vinorelbine with a median survival time of 28 weeks compared to 21 weeks in the control arm and 1-year survival of 32% versus 14%. In a further phase III study comparing in 700 patients vinorelbine alone versus gemcitabine alone versus vinorelbine + gemcitabine, there was no adva